{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-020093","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2023-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.479413+00:00","generated_at":"2026-06-13T07:03:00.100177+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Genprex signs exclusive license for diabetes gene therapy with University of Pittsburgh","bullets":["Exclusive worldwide license for gene therapy using MafB promoter to drive Pdx1 and MafA for Type 1 and Type 2 diabetes.","Preclinical NHP data showed statistically significant decreases in insulin requirements (p<0.001), increased c-peptide (p<0.05), improved glucose tolerance.","Milestone payments up to ~$4.225M plus royalties; technology co-developed by Dr. George Gittes.","Expands existing diabetes gene therapy portfolio; AAV vector delivered via endoscopy."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-020093","json":"https://secwatch.observer/filing/0001437749-23-020093.json","markdown":"https://secwatch.observer/filing/0001437749-23-020093.md","text":"https://secwatch.observer/filing/0001437749-23-020093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774923020093/0001437749-23-020093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774923020093/gnpx20230703_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:03:00.100177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ec30d5eb770327b9c236503c82ef1de37646bb4","claim":"Genprex, Inc. entered into Exclusive License Agreement with University of Pittsburgh - Of the Commonwealth System of Higher Education valued at Initial license fee, annual maintenance fees, running low single digit royalties, minimum annual roy (effective 2023-07-14).","evidence_excerpt":"On July 14, 2023, Genprex, Inc. (“Genprex”) and the University of Pittsburgh - Of the Commonwealth System of Higher Education (“UP”) entered into an Exclusive License Agreement (the “UP License Agreement”), pursuant to which UP granted to Genprex a worldwide, exclusive license under certain patents and related technology, referred to collectively as the licensed technology, and a worldwide, non-exclusive license to use certain related know-how, all related to gene therapy for both Type 1 and Type 2 diabetes using a MafB promoter to drive expression of the Pdx1 and MafA transcription factors.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774923020093/0001437749-23-020093-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"University of Pittsburgh - Of the Commonwealth System of Higher Education"},{"label":"Value","value":"Initial license fee, annual maintenance fees, running low single digit royalties, minimum annual roy"},{"label":"Effective","value":"2023-07-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}